Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit
Cerus Corporation (Nasdaq: CERS) announced that CEO William ‘Obi’ Greenman and CFO Kevin D. Green will participate in the Jefferies Virtual Global Plasma Summit on March 11, 2021, at 11:00 am PT/2:00 pm ET.
A live webcast will be available on the Cerus Investor Relations page, with a replay accessible for two weeks post-event. Cerus focuses on safeguarding the global blood supply with its INTERCEPT Blood System, which is the only pathogen reduction system for platelets and plasma approved by both CE and FDA. The red blood cell system is currently under regulatory review in Europe.
- None.
- None.
Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Jefferies Virtual Global Plasma Summit on Thursday, March 11, 2021 at 11:00 am PT/ 2:00 pm ET.
A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005144/en/
FAQ
What is the date of the Jefferies Virtual Global Plasma Summit featuring Cerus Corporation?
Who will represent Cerus Corporation at the Jefferies Summit?
Where can I watch the Cerus Corporation's participation in the Jefferies Summit?
What is the INTERCEPT Blood System developed by Cerus Corporation?
Is the INTERCEPT Blood System for red blood cells approved?
